|Over a week ago|
Accuray announces launch of new CyberKnife S7 System » 08:5906/1706/17/20
Accuray announces the…
Accuray announces the company has launched the CyberKnife S7 System, which it calls "an innovative device combining speed, advanced precision, and real-time artificial intelligence-driven motion tracking and synchronization treatment delivery for all stereotactic radiosurgery and stereotactic body radiation therapy treatments - in as little as 15 minutes." Joshua Levine, president and CEO at Accuray, said, "With the introduction of the CyberKnife S7 System, Accuray is continuing its legacy of innovation. We believe this new system will make it easier for Geisinger clinicians to successfully deliver SRS and SBRT and achieve their patient-first treatment objectives, a priority for their team and ours."
|Over a month ago|
Accuray withdraws FY20 guidance » 16:0904/2804/28/20
The company said,…
The company said, "Given the continued evolution of the COVID-19 pandemic and the uncertainty surrounding its impact on the global economy and the healthcare industry, Accuray believes it is prudent to withdraw its previous full fiscal year 2020 financial guidance regarding revenue and adjusted EBITDA. The company is carefully monitoring the pandemic and the impact on its business; however, given the uncertainty regarding the pandemic's spread, duration, and impact, the company is currently unable to predict the extent to which the COVID-19 pandemic will impact its future operations and financial results."
Accuray reports Q3 EPS 3c, consensus (4c) » 16:0804/2804/28/20
Reports Q3 revenue…
Reports Q3 revenue $99.5M, consensus $97.26M.
Varian Medical price target lowered to $90 from $100 at JPMorgan » 08:4704/1704/17/20
JPMorgan analyst Tycho…
JPMorgan analyst Tycho Peterson lowered the firm's price target on Varian Medical (VAR) to $90 from $100 and keeps an Underweight rating on the shares. The analyst says a survey of 42 hospital CFOs, radiation department heads and radiation oncologists, as well as the near-term impact from COVID-19, reinforce an Underweight thesis on both Varian and Accuray (ARAY). The analyst sees reduced visibility into future customer demand.
|Over a quarter ago|
Accuray's TomoTherapy System shows improved efficacy in rectal cancer studies » 07:3902/0502/05/20
Accuray announced that…
Accuray announced that two new studies demonstrate the benefits of the TomoTherapy System in the treatment of advanced rectal cancer. Patients enrolled in the two studies received simultaneous daily radiation and a targeted radiation boost over a 25-day time period. The study investigators found that the TomoTherapy platform enabled the delivery of a high dose of radiation, directly to the tumor, through the integrated boost of radiation, while minimizing radiation to organs in close proximity to the targeted tumor. As a result, patients in the studies experienced improved treatment results and reduced side effects. These study outcomes compare favorably to conventional radiotherapy, based on results from other studies.The study published in the Journal of Cancer Research and Clinical Oncology, found treatment with TomoHelical is safe, with low rates of severe toxicity , and radiation delivered with helical TomoTherapy following daily imaging with the platform's integrated imaging capabilities allowed for the reduction of treatment margins around the tumor, so less normal tissue was irradiated. The four-year outcomes showed local tumor control and disease-free survival rates of 88.4% and 74.6%, respectively.
Fly Intel: After Hours Movers » 18:3201/2801/28/20
MTSI, ARAY, MXIM, CMRE, MKSI, AAPL, SYK, CNAT, XLNX, CHRW, EBAY, AMD, MRCY, TRMK, SBUX, BHVN, CERS, ESTA, MTCH
UP AFTER EARNINGS: Macom…
UP AFTER EARNINGS: Macom (MTSI) up 13.4%... Accuray (ARAY) up 10.1%... Maxim Integrated (MXIM) up 3.3%... Costamare (CMRE) up 2.8%... MKS Instruments (MKSI) up 2.0%... Apple (AAPL) up 1.1%... Stryker (SYK) up 0.9%. ALSO HIGHER: Conatus Pharma (CNAT) up 20.0% after entering merger with Histogen. DOWN AFTER EARNINGS: Xilinx (XLNX) down 8.7%... CH Robinson (CHRW) down 7.2%... eBay (EBAY) down 5.2%... AMD (AMD) down 3.9%... Mercury Systems (MRCY) down 1.9%... Trustmark (TRMK) down 1.8%... Starbucks (SBUX) down 1.0%. ALSO LOWER: Biohaven (BHVN) down 10.7% after equity offering... Cerus (CERS) down 5.8% after equity offering... Establishment Labs (ESTA) down 3.4% after equity offering... Match Group (MTCH) down 1.2% after CEO transition. Movers as of 18:15ET.
Accuray raises FY20 adj. EBITDA view to $21M-$26M from $19M-$24M » 16:0901/2801/28/20
Includes approximately $1M of the company's share of expected loss from the joint venture operations in China.
Accuray backs FY20 revenue view $410M-$420M, consensus $412.77M » 16:0801/2801/28/20
The company expects to…
The company expects to generate revenue growth during the second half of fiscal year 2020 compared to the second half of the prior fiscal year.
Accuray reports Q2 EPS 12c with gain, consensus (7c) » 16:0701/2801/28/20
Reports Q2 revenue…
Reports Q2 revenue $98.8M, consensus $97.73M. Net income included a non-cash, special gain of $13M related to the value of the company's capital contribution to the China joint venture in exchange for the company's 49% equity interest in the joint venture. This gain was recorded as non-operating, other income in the second quarter.
Fly Intel: Pre-market Movers » 09:1701/2101/21/20
ARAY, HAL, UBS, TAL, MDR, ORGS, LVS, LL
HIGHER: Accuray (ARAY),…
HIGHER: Accuray (ARAY), up 10% after BTIG analyst Marie Thibault upgraded shares to Buy from Neutral with a $9.50 price target. The analyst notes that the company's long-term revenue growth outlook of 8%-12% announced last week, driven in large part by the contribution from China, is "significantly higher" than its historical performance and the low-to-single digit growth anticipated by consensus. UP AFTER EARNINGS: Halliburton (HAL), up 1%. DOWN AFTER EARNINGS: UBS (UBS), down 4%... TAL Education (TAL), down 8%. ALSO LOWER: McDermott (MDR), down 14% after announcing that it has the support of more than two-thirds of all its funded debt creditors for a restructuring transaction that will equitize nearly all the company's funded debt, eliminating over $4.6B of debt. The restructuring transaction will be implemented through a prepackaged Chapter 11 process that will be financed by a debtor-in-possession financing facility of $2.81B... Las Vegas Sands (LVS), down 5% after Morgan Stanley analyst Thomas Allen downgraded the stock to Equal Weight from Overweight. He continues to see the stock as "the mass market play on Macau" and his Macau mass market growth forecast for 2020 trails what Consensus Metrix suggests is the U.S. analyst forecast average... Orgenesis (ORGS), down 7% after announcing it has entered into a definitive securities purchase agreement for the sale of 2,200,000 shares of the company's common stock in a private placement at a purchase price of $4.20 per share and warrants to purchase up to 1,000,000 shares of common stock at an exercise price of $5.50 per share... Lumber Liquidators (LL), down 6% after Morgan Stanley analyst Simeon Gutman downgraded shares to Underweight from Equal Weight with a price target of $5, down from $9.